MS-PPOH
目录号 : GC19483
A potent, selective inhibitor of microsomal CYP450 epoxidase activity
Cas No.:206052-02-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Arachidonic acid is converted by microsomal CYP450 enzymes to a variety of epoxides, ω-1 and ω-hydroxylated compounds via what is known as the epoxidase pathway.[1],[2],[3] MS-PPOH is a selective inhibitor of the epoxygenation reactions catalyzed by specific CYP450 isozymes.[4]. MS-PPOH inhibits the formation of arachidonate 11,12-epoxides by CYP4A2 and CYP4A3 enzymes with an IC50 value of 13 µM, but has no effect on the formation of 20-HETE, the ω-hydroxylation product of CYP4A1.[5]
Reference:
[1]. Capdevila, J.H., Karara, A., Waxman, D.J., et al. Cytochrome P-450 enzyme-specific control of the regio- and enantiofacial selectivity of the microsomal arachidonic acid epoxygenase The Journal of Biological Chemisty 265, 10865-10871 (1990).
[2]. Sacerdoti, D., Abraham, N.G., McGiff, J.C., et al. Renal cytochrome P-450-dependent metabolism of arachidonic acid in spontaneously hypertensive rats Biochemical Pharmacology 37, 521-527 (1988).
[3]. Fitzpatrick, F.A., and Murphy, R.C. Cytochrome P-450 metabolism of arachidonic acid: Formation and biological actions of “epoxygenase”-derived eicosanoids Pharmacol. Rev. 40(4), 229-241 (1989).
[4]. Imig, J.D., Falck, J.R., and Inscho, E.W. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness British Journal of Pharmacology 127, 1399-1405 (1999).
[5]. Wang, M.H., Brand-Schieber, E., Zand, B.A., et al. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: Characterization of selective inhibitors Journal of Pharmacology and Experimental Therapeutics 284(3), 966-973 (1998).
| Cas No. | 206052-02-0 | SDF | |
| 化学名 | N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide | ||
| Canonical SMILES | CCCOc1ccccc1CCCCCC(=O)NS(=O)(=O)C | ||
| 分子式 | C16H21NO4S | 分子量 | 323.4 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2)(1:2): .30 mg/ml,Ethanol: 25 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0921 mL | 15.4607 mL | 30.9215 mL |
| 5 mM | 0.6184 mL | 3.0921 mL | 6.1843 mL |
| 10 mM | 0.3092 mL | 1.5461 mL | 3.0921 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。